Full Name
Dr. Mark J. Roschewski MD
Job Title
Attending Physician, Lymphoma Department
Company/Affiliation
Memorial Sloan Kettering Cancer Center
Speaker Bio
Mark Roschewski, MD, is a clinician-scientist who is currently an Attending Physician at Memorial Sloan Kettering Cancer Center in New York City. He began his career at Walter Reed Army Medical Center as an active-duty physician in the Army. After completing 12 years of active-duty Army service, he transferred to the U.S. Public Health Service and joined the faculty at the National Cancer Institute, where he served as the Deputy Chief of the Lymphoid Malignancies Branch until 2025. He retired from the USPHS as a CAPT in 2023.
Dr. Roschewski earned his B.A. degrees at the University of Notre Dame and received his medical degree from the University of Nebraska Medical Center in Omaha, NE. He completed both internship and residency in Internal Medicine at Eisenhower Army Medical Center in Augusta, GA, and a Hematology-Oncology fellowship in Medical Oncology at Walter Reed Army Medical Center in Washington, DC.
The primary goal of his research team is to translate novel findings from the molecular biology of lymphoma into innovative therapies for lymphomas such as large B-cell lymphoma (LBCL), Burkitt’s lymphoma, follicular lymphoma, mantle cell lymphoma, EBV-associated lymphomas, and CNS lymphomas. He pioneered studies to develop highly effective therapy for subtypes of LBCL such as primary mediastinal B-cell lymphoma and Burkitt’s lymphoma. In addition, he conducted studies that demonstrated the effectiveness of targeted therapies, including inhibitors of Bruton tyrosine kinase (BTK), ibrutinib, in both primary and secondary CNS lymphomas, and recently he co-developed a multi-targeted regimen (ViPOR) for relapsed LBCL. His translational research interests include studying circulating tumor DNA (ctDNA) as a predictive and prognostic biomarker in LBCL and other lymphoma subtypes.
Dr. Roschewski is frequently invited to give presentations on his research to both national and international audiences, and he has published in high-impact scientific journals. He is often a reviewer for various scientific journals, including New England Journal of Medicine, Blood, Cancer Cell, Nature, Lancet Oncology, and Journal of Clinical Oncology. He joined the editorial board of Blood in 2024.
Dr. Roschewski earned his B.A. degrees at the University of Notre Dame and received his medical degree from the University of Nebraska Medical Center in Omaha, NE. He completed both internship and residency in Internal Medicine at Eisenhower Army Medical Center in Augusta, GA, and a Hematology-Oncology fellowship in Medical Oncology at Walter Reed Army Medical Center in Washington, DC.
The primary goal of his research team is to translate novel findings from the molecular biology of lymphoma into innovative therapies for lymphomas such as large B-cell lymphoma (LBCL), Burkitt’s lymphoma, follicular lymphoma, mantle cell lymphoma, EBV-associated lymphomas, and CNS lymphomas. He pioneered studies to develop highly effective therapy for subtypes of LBCL such as primary mediastinal B-cell lymphoma and Burkitt’s lymphoma. In addition, he conducted studies that demonstrated the effectiveness of targeted therapies, including inhibitors of Bruton tyrosine kinase (BTK), ibrutinib, in both primary and secondary CNS lymphomas, and recently he co-developed a multi-targeted regimen (ViPOR) for relapsed LBCL. His translational research interests include studying circulating tumor DNA (ctDNA) as a predictive and prognostic biomarker in LBCL and other lymphoma subtypes.
Dr. Roschewski is frequently invited to give presentations on his research to both national and international audiences, and he has published in high-impact scientific journals. He is often a reviewer for various scientific journals, including New England Journal of Medicine, Blood, Cancer Cell, Nature, Lancet Oncology, and Journal of Clinical Oncology. He joined the editorial board of Blood in 2024.
Speaking At
